← 返回

肿瘤微环境响应性多功能“特洛伊木马”诊疗纳米平台用于磁共振成像引导的多模式协同抗肿瘤治疗

英文原题:Tumor microenvironment-responsive versatile "Trojan horse" theranostic nanoplatform for magnetic resonance imaging-guided multimodal synergistic antitumor treatment.

查看英文原题

Tumor microenvironment-responsive versatile "Trojan horse" theranostic nanoplatform for magnetic resonance imaging-guided multimodal synergistic antitumor treatment.

PubMed 2022/05/17(内容时间) Acta Biomater Q1 · IF 10.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

开发了一种基于自然杀伤(NK)-92细胞膜伪装的介孔MnO2包覆Au@Pd(Au@Pd@MnO2)纳米颗粒(记为APMN NPs)的多功能仿生诊疗纳米平台,用于磁共振(MR)成像引导的多模式协同抗肿瘤治疗。在该核壳纳米结构中,Au@Pd核心可诱导近红外(NIR)激活的热效应和纳米酶催化活性,而介孔MnO2壳不仅提供了高载药能力、肿瘤微环境(TME)触发的MR成像和药物释放,还赋予了过氧化氢酶、谷胱甘肽过氧化物酶和类Fenton活性。

此外,NK-92细胞膜伪装赋予该NPs增强的肿瘤靶向能力、免疫逃逸功能和膜蛋白介导的肿瘤摄取特性。载阿霉素的APMN(D-APMN)NPs表现出TME响应性药物释放特性。

此外,细胞摄取、体内MR成像和NIR热成像证实了这些仿生NPs的主动肿瘤靶向能力和TME响应性MR成像特性。抗肿瘤疗效试验、组织学分析和血液生化谱表明,所开发的D-APMN NPs在荷瘤裸鼠中具有高抗肿瘤活性和生物安全性。

因此,所开发的APMN NPs作为一种智能且全面的诊疗纳米平台,在基于光热治疗、化学动力学治疗和化疗的肿瘤特异性生物成像和TME响应性多模式治疗方面具有巨大潜力。意义声明:探索智能且全面的诊疗纳米平台以有效整合肿瘤特异性生物成像和TME响应性多模式治疗是一项挑战。

在此,我们成功开发了一种基于NK-92细胞膜伪装的介孔MnO2包覆Au@Pd纳米颗粒(APMN NPs)的新型多功能仿生诊疗纳米平台,用于潜在的MR成像引导的多模式协同抗肿瘤治疗。这些NPs能够在单一纳米平台中整合NK-92细胞膜、Au@Pd核心和介孔MnO2壳的独特结构、光学、多重催化、顺磁和生物学优势。NK-92细胞膜伪装赋予NPs增强的肿瘤靶向能力、免疫逃逸功能和膜蛋白介导的肿瘤摄取特性。

本研究获得的新信息可能有助于促进新型TME响应性多功能“特洛伊木马”诊疗纳米平台的发展,用于高效的MR成像引导的多模式协同治疗。

展开英文摘要原文

A natural killer (NK)-92 cell membrane-camouflaged mesoporous MnO 2 -enveloped Au@Pd (Au@Pd@MnO 2 ) nanoparticles (denoted as APMN NPs)-based versatile biomimetic theranostic nanoplatform was developed for magnetic resonance (MR) imaging-guided multimodal synergistic antitumor treatments.

In this core-shell nanostructure, an Au@Pd core induced near-infrared (NIR)-activatable hyperthermal effects and nanozyme catalytic activity, while a mesoporous MnO 2 shell not only afforded a high drug-loading capability, tumor microenvironment (TME)-triggered MR imaging and drug release, but also endowed catalase-, glutathione peroxidase-, and Fenton-like activities.

Furthermore, the NK-92 cell membrane camouflaging endowed the NPs with enhanced tumor-targeting capability, immune escape function, and membrane protein-mediated tumoral uptake property. The doxorubicin-loaded APMN (D-APMN) NPs exhibited TME-responsive drug release properties.

Furthermore, the cellular uptake, in vivo MR imaging, and NIR thermal imaging confirmed the active tumor-targeting capability and TME-responsive MR imaging property of these biomimetic NPs. An antitumor efficacy test, histological analyses, and blood biochemical profiles suggested that the developed D-APMN NPs possessed a high antitumor activity and biosafety in tumor-bearing nude mice.

Therefore, the developed APMN NPs held great potential as an intelligent and comprehensive theranostic nanoplatform for tumor-specific bioimaging and TME-responsive multimodality treatment based on photothermal therapy, chemodynamic therapy, and chemotherapy. STATEMENT OF SIGNIFICANCE: Exploring intelligent and comprehensive theranostic nanoplatforms to integrate tumor-specific bioimaging and TME-responsive multimodal therapy effectively is a challenge.

Herein, we successfully developed a new kind of NK-92 cell membrane-camouflaged mesoporous MnO 2 -enveloped Au@Pd nanoparticles (APMN NPs)-based versatile biomimetic theranostic nanoplatform for the potential MR imaging-guided multimodal synergistic antitumor treatments. These NPs could integrate unique structural, optical, multiple-catalytic, paramagnetic, and biological merits of NK-92 cell membrane, Au@Pd cores and mesoporous MnO 2 shell in a single nanoplatform.

The NK-92 cell membrane camouflaging endowed the NPs with enhanced tumor-targeting capability, immune escape function, and membrane protein-mediated tumoral uptake property. The new information obtained from this study may be beneficial to promote the development of novel TME-responsive versatile "Trojan horse" theranostic nanoplatforms for efficient MR imaging-guided multimodal synergistic treatment.

论文信息

作者
Huang Q、Pan Y、Wang M、Liu Z、Chen H、Wang J、Zhao Z、Zhang Y
第一作者单位
Public experimental research center of Xuzhou Medical University, Xuzhou, 221004, China.China
通讯作者单位
School of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, China; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, PR China. Electronic address: yanzhuozhang@xzhmu.edu.cn.China
文献类型
非美国政府资助研究
期刊
Acta biomaterialia2022 Jul 15
原文标识
PubMed 35595202 · DOI 10.1016/j.actbio.2022.05.024